LLY: Eli Lilly and Company Stock

by  •  • Comments Off on LLY: Eli Lilly and Company Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 654,235.43
Enterprise Value ($M) 676,868.53
Book Value ($M) 11,307.40
Book Value / Share 12.55
Price / Book 57.86
NCAV ($M) -27,415.60
NCAV / Share -30.44
Price / NCAV -23.86

Profitability (mra)
Return on Invested Capital (ROIC) 0.14
Return on Assets (ROA) 0.10
Return on Equity (ROE) 0.46

Liquidity (mrq)
Quick Ratio 0.73
Current Ratio 0.94

Balance Sheet (mrq) ($M)
Current Assets 25,727.00
Assets 64,006.30
Liabilities 53,142.60
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 34,124.10
Operating Income 10,325.40
Net Income 5,240.40
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 4,240.10
Cash from Investing -7,152.70
Cash from Financing 3,495.60

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Vanguard Group Inc 7.54 -2.49
02-09 13G/A Pnc Financial Services Group, Inc. 5.43 -0.56
01-29 13G/A BlackRock Inc. 6.80 -1.67
01-26 13G/A Lilly Endowment Inc 10.51 -3.09

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-21 10-K United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023 Commission file number 001-06351 ELI LI
2023-11-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 COMMISSION FILE NUMBER 001-635
2023-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 COMMISSION FILE NUMBER 001-6351 ELI
2023-04-27 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 COMMISSION FILE NUMBER 001-6351 EL

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-22 249,410 1,679,069 14.85
2024-04-19 426,770 3,505,526 12.17
2024-04-18 251,200 1,717,347 14.63
2024-04-17 565,917 3,069,367 18.44

(click for more detail)

Similar Companies
ELAN – Elanco Animal Health Incorporated HYAC – Haymaker Acquisition Corp. 4
JNJ – Johnson & Johnson MRK – Merck & Co., Inc.
NUVB – Nuvation Bio Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Eli Lilly and Company